RxDoctor Payments Data

Chad McElroy, MD

Family Medicine · Moulton, ALNPI 1154472355

Payments from drug & device makers

$14,224in general payments, 2019–2025

Across 953 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$995
  • Amgen$875
  • Kowa Pharmaceuticals America, Inc.$652
  • Novo Nordisk$649
  • plus $8K from 44 others

What the payments were for

  • Food & beverage$14,10399%
  • Education$1211%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,224 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$115,163
Medicare patients
197
Services billed
1,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide202$225,999
OzempicSemaglutide118$131,711
EnbrelEtanercept13$94,403
JardianceEmpagliflozin98$93,478
FarxigaDapagliflozin Propanediol100$82,508
TrulicityDulaglutide67$63,366
EliquisApixaban84$58,145
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog88$50,146
VraylarCariprazine Hcl35$49,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$45,090
RexultiBrexpiprazole25$40,696
XareltoRivaroxaban32$34,290
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$34,282
RybelsusSemaglutide27$29,273
MyrbetriqMirabegron51$29,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,107$289,365269 claims
Novo NordiskOzempic, Rybelsus$649$160,984145 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$995$124,926174 claims
AmgenEnbrel$875$94,40313 claims
Boehringer IngelheimJardiance$335$93,47898 claims
AbbVieVraylar, Linzess$1,852$60,31551 claims
PfizerEliquis$589$58,14584 claims
GSKTrelegy Ellipta$137$45,09049 claims
Otsuka America Pharmaceutical, Inc.Rexulti$212$40,69625 claims
MerckJanuvia, Janumet Xr$195$36,42136 claims
Johnson & JohnsonXarelto$415$34,29032 claims
Astellas Pharma US IncMyrbetriq$264$29,00751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Moulton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →